Sep 10, 2019
RegeneRx to Present at Fall Investor Summit on September 17
Sep 04, 2019
RegeneRx Modifies September Conference Schedule
Jul 29, 2019
RegeneRx's RGN-137 for Epidermolysis Bullosa Subject of New Article in Seeking Alpha Investor Site
Jul 16, 2019
RegeneRx to Present at the Rodman & Renshaw and the Fall Investor Summit Conferences in September 2019
May 28, 2019
RegeneRx Receives Final Payment from Convertible Debt Financing
May 13, 2019
First Patient Enrolled in RegeneRx JV Phase 3 Dry Eye Trial
Apr 22, 2019
RegeneRx Publishes Annual Letter to Shareholders
Mar 27, 2019
RegeneRx to Present at 2019 Spring Investor Summit
Mar 26, 2019
RegeneRx and Lee's Pharm to Accelerate RGN-259 Development in China
Mar 21, 2019
RegeneRx Announces New Board Member
Feb 27, 2019
RegeneRx Closes $1.3 Million Convertible Debt Financing
Feb 12, 2019
RegeneRx's U.S. Joint Venture Initiates Key Phase 3 Dry Eye Clinical Trial with RGN-259
Jan 04, 2019
RegeneRx Update on Dry Eye and EB Clinical Trials
Oct 29, 2018
RegeneRx Partner Updates on Clinical Trials
Sep 06, 2018
World Health Organization Recommends INN for Thymosin Beta 4 as "timbetasin"
Aug 02, 2018
RegeneRx Licensee GtreeBNT Enters into Joint Venture to Globally Develop RGN-137 for Treatment of Epidermolysis Bullosa
Jul 16, 2018
RGN-259 (Tb4) Improves Clinically Important Dry Eye Efficacies in Comparison with Prescription Drugs in Dry Eye Model
Jun 13, 2018
RegeneRx Holds Annual Meeting
May 29, 2018
RegeneRx Corrects Annual Meeting Date to Wednesday, June 13, 2018
May 02, 2018
ReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eye Syndrome in a Mouse Model at ARVO